| 1 min read
Register for free to listen to this article
Listen with Speechify
0:00
1:00
PALO ALTO, Calif.—The difference between a salve and a poison can be simply a question of dose. Many drugs, such as the anticoagulant warfarin, have a very narrow therapeutic index, meaning too much or too little of the drug can lead to disaster for the patient. Sometimes, this challenge is exacerbated by large effective-dose variations between patients.
 
Researchers at Stanford University and Roche Bioscience approached this problem with computational pharmacogenetics in mice, presenting their work in Nature Biotechnology.
 
Initially, the researchers examined the processing of warfarin in mice to identify individual metabolic variations. They then performed computational haplotype analysis of specific P450 enzymes to look for correlations with the metabolic characteristics of the mice. The researchers found strong correlations between mouse strains that linked genetic legacy with drug metabolism. They confirmed their computational findings experimentally, noting that the degree of warfarin metabolism was directly linked to the amount of CYP2c29 P450 enzyme.
 
"This research and the computational method can help scientists and clinicians better understand the drugs they are using, as well as the diseases they target," stated Dr. Gary Peltz, head of genetics and genomics at Roche. "It can also be used to identify genetic susceptibility factors affecting drug-induced toxicity."

About the Author

Related Topics

Loading Next Article...
Loading Next Article...
Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

A black mosquito is shown on pink human skin against a blurred green backdrop.

Discovering deeper insights into malaria research

Malaria continues to drive urgent research worldwide, with new therapies and tools emerging to combat the parasite’s complex lifecycle and global burden.
Three burgundy round and linear conformations of oligonucleotides are shown against a black background.

Accelerating RNA therapeutic testing with liver microphysiological platforms

Researchers can now study oligonucleotide delivery and efficacy in a system that models a real human liver.
A 3D-rendered illustration of a eukaryotic cell highlighting organelles such as the nucleus, endoplasmic reticulum, mitochondria, and cytoskeletal structures in pink and purple tones.

Shining light on the subcellular proteome

Discover how innovative proteomics tools help researchers peer into once inaccessible organelles, allowing for new targets for drug discovery and development.
Drug Discovery News March 2025 Issue
Latest IssueVolume 21 • Issue 1 • March 2025

March 2025

March 2025 Issue

Explore this issue